JUBILANT PHARMOVA Financial Statement Analysis
|
||
|
The Revenues of JUBILANT PHARMOVA have increased by 0.52% YoY .
The Earnings Per Share (EPS) of JUBILANT PHARMOVA has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
JUBILANT PHARMOVA Last 5 Annual Financial Results
[BOM: 530019|NSE : JUBLPHARMA]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹6,130 Cr | ₹6,099 Cr | ₹5,976 Cr | ₹9,111 Cr | ₹7,518 Cr |
| Expenses | ₹4,974 Cr | ₹4,702 Cr | ₹4,428 Cr | ₹7,372 Cr | ₹5,999 Cr |
| Operating Profit (Excl OI) | ₹1,156 Cr | ₹1,396 Cr | ₹1,548 Cr | ₹1,739 Cr | ₹1,518 Cr |
| Other Income | ₹11 Cr | ₹18 Cr | ₹37 Cr | ₹36 Cr | ₹40 Cr |
| Interest | ₹145 Cr | ₹184 Cr | ₹200 Cr | ₹220 Cr | ₹284 Cr |
| Depreciation | ₹382 Cr | ₹349 Cr | ₹340 Cr | ₹371 Cr | ₹415 Cr |
| Profit Before Tax | ₹630 Cr | ₹871 Cr | ₹1,013 Cr | ₹904 Cr | ₹859 Cr |
| Profit After Tax | ₹413 Cr | ₹574 Cr | ₹678 Cr | ₹577 Cr | ₹634 Cr |
| Consolidated Net Profit | ₹414 Cr | ₹836 Cr | ₹898 Cr | ₹574 Cr | ₹643 Cr |
| Earnings Per Share (Rs) | ₹-3.83 | ₹26.01 | ₹52.51 | ₹56.39 | ₹36.07 |
| PAT Margin (%) | -1.03 | 6.74 | 9.41 | 11.34 | 6.33 |
| ROE(%) | -1.21 | 8.21 | 11.09 | 13.02 | 12.97 |
| ROCE(%) | 2.53 | 9.97 | 12.02 | 12.20 | 13.06 |
| Total Debt/Equity(x) | 0.63 | 0.55 | 0.55 | 0.83 | 1.01 |
Key Financials |
||
| Market Cap | : | ₹ 10,779.0 Cr |
| Revenue (TTM) | : | ₹ 6,622.3 Cr |
| Net Profit(TTM) | : | ₹ -3.4 Cr |
| EPS (TTM) | : | ₹ -0.2 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| JUBILANT PHARMOVA | 1.7% | 18.7% | 122.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
| CIPLA | 4.5% | -3.1% | 52.8% |
| DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
| ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
| DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
| MANKIND PHARMA | 2.7% | 12.4% | NA |
| TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
| LUPIN | 3.1% | -1.1% | 127.4% |
JUBILANT PHARMOVA Revenues
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | 0.52 % |
| 5 Yr CAGR | -4.97 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹6,130 Cr | 0.52 | |
| Mar2022 | ₹6,099 Cr | 2.05 | |
| Mar2021 | ₹5,976 Cr | -34.41 | |
| Mar2020 | ₹9,111 Cr | 21.19 | |
| Mar2019 | ₹7,518 Cr | - | |
JUBILANT PHARMOVA Operating Profit
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | -17.20 % |
| 5 Yr CAGR | -6.58 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,156 Cr | -17.20 | |
| Mar2022 | ₹1,396 Cr | -9.79 | |
| Mar2021 | ₹1,548 Cr | -10.99 | |
| Mar2020 | ₹1,739 Cr | 14.53 | |
| Mar2019 | ₹1,518 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -17.64 % |
| 5 Yr CAGR | -1.70 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 18.86% | -17.64 | |
| Mar2022 | 22.9% | -11.58 | |
| Mar2021 | 25.9% | 35.67 | |
| Mar2020 | 19.09% | -5.50 | |
| Mar2019 | 20.2% | - | |
JUBILANT PHARMOVA Profit After Tax
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | -50.48 % |
| 5 Yr CAGR | -10.42 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹414 Cr | -50.48 | |
| Mar2022 | ₹836 Cr | -6.94 | |
| Mar2021 | ₹898 Cr | 56.36 | |
| Mar2020 | ₹574 Cr | -10.63 | |
| Mar2019 | ₹643 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | -1.03 % | Negative | |
| Mar2022 | 6.74 % | -28.37 | |
| Mar2021 | 9.41 % | -17.02 | |
| Mar2020 | 11.34 % | 79.15 | |
| Mar2019 | 6.33 % | - | |
JUBILANT PHARMOVA Earnings Per Share (EPS)
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹-3.83 | Negative | |
| Mar2022 | ₹26 | -50.47 | |
| Mar2021 | ₹53 | -6.88 | |
| Mar2020 | ₹56 | 56.33 | |
| Mar2019 | ₹36 | - | |
JUBILANT PHARMOVA Return on Capital Employed (ROCE)
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | -74.62 % |
| 5 Yr CAGR | -33.66 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 2.53% | -74.62 | |
| Mar2022 | 9.97% | -17.05 | |
| Mar2021 | 12.02% | -1.48 | |
| Mar2020 | 12.2% | -6.58 | |
| Mar2019 | 13.06% | - | |
JUBILANT PHARMOVA Share Price vs Sensex
| Current Share Price | : | ₹676.7 |
| Current MarketCap | : | ₹ 10,779.0 Cr |
| Updated EOD on | : | Apr 25,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JUBILANT PHARMOVA | 1.7% |
18.7% |
122.1% |
| SENSEX | 1.3% |
2.6% |
24% |
JUBILANT PHARMOVA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | 3.2% | 12.8% | 65.7% |
| S&P BSE 250 SMALLCAP | 2.5% | 12.8% | 64.9% |
| S&P BSE MIDSMALLCAP | 2.4% | 10.7% | 64.9% |
| S&P BSE 400 MIDSMALLCAP | 1.9% | 9.9% | 59.4% |
| S&P BSE ALLCAP | 1.6% | 6% | 40.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP250 | 2.8% | 13.8% | 71.1% |
| NIFTY MID SMALL400 | 2.1% | 10.7% | 62.3% |
| NIFTY500 MULTICAP 50:25:25 | 1.8% | 7.7% | 48.1% |
| NIFTY 500 | 1.5% | 5.7% | 39.5% |
You may also like the below Video Courses
FAQ about JUBILANT PHARMOVA Financials
How the annual revenues of JUBILANT PHARMOVA have changed ?
The Revenues of JUBILANT PHARMOVA have increased by 0.52% YoY .
How the Earnings per Share (EPS) of JUBILANT PHARMOVA have changed?
The Earnings Per Share (EPS) of JUBILANT PHARMOVA has decreased by Negative YoY .
Check out Intrinsic Value of Peers of JUBILANT PHARMOVA
Compare Stock Analytics of Peers of JUBILANT PHARMOVA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
